Remove Clinical Development Remove Genomics Remove In-Vitro
article thumbnail

The Biotech Effect

Pharmaceutical Technology

“However, around the time of the Human Genome Project, there was a ‘land grab’ for the new technologies as big pharmaceuticals tried to catch up paying high prices to access technology platforms in areas such as genomics and high throughput screening.” “Biotechnology has exploded across the industry. .

Antibody 100
article thumbnail

BMS joins forces with insitro to develop neurodegenerative treatments

pharmaphorum

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cardiac Biomarkers in Cardiovascular Clinical Trials: Caveats and Considerations

XTalks

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

article thumbnail

Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19

The Pharma Data

Preclinical data suggest VIR-7831 targets a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop. About the VIR-7831 Clinical Development Programme. The interim analysis included 291 patients in the treatment arm and 292 patients in the placebo arm.

article thumbnail

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

The Pharma Data

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR 52
article thumbnail

Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

The Pharma Data

Roche’s Chief Medical Officer and Head of Global Product Development. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients.

article thumbnail

Top 10 Biotech Trends for 2025

XTalks

This blog highlights the top 10 biotech trends for 2025, showcasing cutting-edge technologies and approaches that promise to redefine patient care, accelerate drug development and expand our understanding of human biology. Related: Biotech IPOs in 2024: Navigating the New Wave of Innovation 1.